Generation Bio is a biotechnology company developing a breakthrough class of genetic medicines to enable a new generation of people unaffected by inherited disease. The company's therapies are based on its proprietary GeneWave technology, which delivers durable, high levels of gene expression and can be re-dosed to titrate to effect and to sustain impact over a lifetime.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/27/18 | $100,000,000 | Series B |
Casdin Capital Deerfield Management Company, L.P. Fidelity Management & Research Company  Foresite Capital Invus | undisclosed |
| 01/10/20 | $110,000,000 | Series C |
Atlas Venture Casdin Capital Deerfield Management Company, L.P. Farallon Capital Management Fidelity Management & Research Company Foresite Capital Invus T. Rowe Price Associates Wellington Management Company | undisclosed |
